VREOF Vireo Growth Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1771706 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY255.9%
TTM net income YoY-2.2%
TTM EPS YoY149.6%
Revenue 3-yr CAGR101.0%
Net income 3-yr CAGR—
Margins
Gross margin47.4%
Operating margin1.3%
Net margin-9.6%
FCF margin-14.6%
EBITDA margin5.4%
Returns
ROE-17.5%
ROA-6.2%
ROIC (approx.)3.3%
Asset turnover0.64x
Leverage & solvency
Liabilities / assets65.3%
Debt / equity0.00x
Current ratio1.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.58x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue20.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $253.70M | $209.30M | $106.20M | $104.51M | $91.70M | $48.10M | $24.50M | $25.02M |
| Gross profit | $107.80M | $95.30M | $59.30M | $56.88M | $37.40M | $20.40M | $12.40M | $12.65M |
| SG&A expense | $82.00M | $75.80M | $30.80M | $31.58M | $33.70M | $16.60M | $7.40M | $6.54M |
| Operating income | $7.60M | -$6.30M | $9.00M | -$1.81M | $800,000 | -$2.00M | $2.00M | -$841,550 |
| Interest expense | $11.50M | $7.60M | — | — | $3.90M | $4.70M | $7.60M | $7.58M |
| Pretax income | $4.00M | $14.20M | -$4.20M | -$12.05M | -$13.00M | -$10.10M | -$4.80M | -$11.36M |
| Net income | -$24.00M | -$100,000 | -$20.30M | -$20.37M | -$26.30M | -$14.90M | -$6.50M | -$15.70M |
| EBITDA | $13.70M | -$400,000 | $13.00M | $10.10M | $3.20M | -$700,000 | $2.60M | -$205,967 |
| EPS (basic) | -0.49 | 0.00 | -0.02 | — | -0.83 | -0.80 | -0.02 | — |
| EPS (diluted) | -0.49 | 0.00 | -0.02 | — | -0.83 | -0.80 | -0.02 | — |
| Weighted avg. shares (diluted) | 49.22M | 45.09M | 1.08B | — | 31.66M | 18.64M | 366.80M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $106.80M | $122.70M | $137.80M | $122.50M | $117.50M | $106.10M | $86.20M | $91.60M |
| Short-term investments | — | $1.00M | $1.00M | $1.00M | $1.01M | $1.00M | — | — |
| Receivables | — | — | $14.10M | $12.70M | $11.19M | $9.14M | $2.42M | $2.87M |
| Inventory | $158.80M | $149.40M | $76.10M | $60.00M | $53.90M | $63.03M | $23.34M | $21.67M |
| Current assets | $382.30M | $394.50M | $258.30M | $305.10M | $307.96M | $312.79M | $228.43M | $230.37M |
| PP&E, net | $282.80M | $280.70M | $232.30M | $217.50M | $121.24M | $110.66M | $32.84M | $32.31M |
| Goodwill | $178.10M | $161.10M | $123.80M | $87.50M | $97.29M | $72.64M | — | $0 |
| Intangibles | $268.00M | $218.70M | $194.00M | $117.50M | $89.65M | $86.17M | $7.69M | $7.90M |
| Total assets | $1.42B | $1.27B | $928.80M | $817.20M | $678.92M | $659.34M | $277.05M | $278.86M |
| Current liabilities | $195.10M | $390.70M | $215.80M | $191.70M | $234.91M | $243.52M | $137.66M | $135.47M |
| Total liabilities | $929.80M | $831.20M | $634.70M | $509.80M | $432.61M | $390.76M | $226.61M | $223.30M |
| Shareholders' equity | $494.80M | $442.50M | $294.10M | $307.40M | $246.30M | $268.60M | $50.50M | $55.50M |
| Cash flow statement | ||||||||
| Operating cash flow | $4.50M | $2.40M | $11.90M | $18.66M | -$6.80M | -$4.80M | -$3.40M | -$6.44M |
| Capital expenditure | $6.80M | $108.20M | $10.80M | $9.86M | $13.70M | $3.70M | $1.10M | $2.72M |
| Free cash flow | -$2.30M | -$105.80M | $1.10M | $8.79M | -$20.50M | -$8.50M | -$4.50M | -$9.16M |
| Investing cash flow | -$7.70M | -$69.70M | $8.00M | -$9.42M | -$14.70M | $34.00M | -$1.10M | -$2.61M |
| Financing cash flow | -$12.70M | $52.20M | -$4.60M | -$4.28M | $32.90M | -$9.30M | -$900,000 | $93.38M |
| Depreciation & amortization | $6.10M | $5.90M | $4.00M | $11.91M | $2.40M | $1.30M | $600,000 | $635,583 |
| Stock-based compensation | $6.00M | $7.50M | $7.00M | $9.16M | $4.01M | $4.20M | $1.50M | $2.20M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.